“`html BREAKING: John Mauceri‘s Cardiac Surgery Success BREAKING: John Mauceri’s Cardiac Surgery Success Award-winning conductor John Mauceri is back on stage after undergoing cardiac surgery to treat a… The post John Mauceri: Conductor Returns to Stage After Health Recovery appeared first on NewsyList. Source link
John Mauceri, an award-winning music conductor, author, and recording artist, is celebrating his return to the stage in better health following specialized cardiac surgery at NYU Langone Health to treat a rare and life-threatening heart condition. Maestro Mauceri’s illustrious career has taken him to the world’s most prestigious opera houses, symphony halls, Broadway stages and … Read more
Emerging data about benefits of the newer weight-loss drugs for some chronic skin conditions suggests their potential use in dermatology, as well as a role for dermatologists in obesity management. Glucagon like peptide 1 receptor agonist (GLP-1 RA) medications began as treatments for type 2 diabetes (T2D), then emerged as weight-loss drugs. The newer generation … Read more
About six years ago, Mike Braucher, 58, had to stop playing basketball with his sons because of joint pain. After a few pain medications didn’t work, he was eventually referred to a rheumatologist who provided a more accurate diagnosis: Psoriatic arthritis, a chronic condition marked by joint pain and skin symptoms. Braucher, like many with … Read more
Psoriasis, which affects approximately 7.5 million people in the United States, is a chronic, immune-mediated dermatological disorder characterized by keratinocyte hyperproliferation, often presenting as erythematous, scaly plaques on the skin. In some cases, it is accompanied by psoriatic arthritis (PsA), a seronegative oligoarthritis marked by progressive joint pain and destruction. While pharmacologic interventions, including biologic … Read more
Aaron M. Drucker, MD, ScM Credit: ICES Biologic treatments for psoriasis and psoriatic arthritis (PsA) that target interleukin (IL)-12, IL-23, or IL-17 are associated with lower serious infection rates among older adults with these psoriatic diseases, according to new findings.1 These data suggest the potential safety benefits of these biologics for older adults who are … Read more
Older adults with psoriatic disease may face a lower risk of serious infections when treated with biologics targeting interleukin (IL)-12, IL-23, or IL-17, according to a new study.1 The study found that these biologics were associated with fewer hospitalizations for infections compared with other systemic treatments. Biologics targeting interleukin (IL)-12, IL-23, or IL-17 reduced serious … Read more
The need to recognize and manage chronic nociplastic pain has become integral to rheumatology practice, as research over the past half-decade has affirmed that when central sensitization is present, patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), axial spondyloarthritis (AxSpA), and other rheumatologic diseases are less responsive — or nonresponsive — to peripherally and axially … Read more
TOPLINE: According to a study of over five million patients with a neoplasm, those who received an immune checkpoint inhibitor (ICI) faced a 26% higher risk for rheumatoid arthritis (RA) than those receiving other types of cancer therapy. METHODOLOGY: Researchers conducted this retrospective observational study using data from the global federated research network TriNetX to … Read more